Lawsuit for Investors in Shares of Seattle Genetics, Inc. (NASDAQ:SGEN) over Alleged Misleading Statements

A lawsuit was filed on behalf of investors in Seattle Genetics, Inc. (NASDAQ:SGEN) shares over alleged securities laws violations. Deadline: March 13, 2017. NASDAQ:SGEN investors should contact the Shareholders Foundation.

Logo

San Diego, CA -- (SBWire) -- 01/18/2017 --An investor, who purchased shares of Seattle Genetics, Inc. (NASDAQ:SGEN), filed a lawsuit in Washington over alleged Securities Laws violations by Seattle Genetics, Inc. in connection with certain allegedly false and misleading statements.

Investors who purchased shares of Seattle Genetics, Inc. (NASDAQ:SGEN) have certain options and for certain investors are short and strict deadlines running. Deadline: March 13, 2017. NASDAQ:SGEN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The plaintiff alleges on behalf of certain purchasers of Seattle Genetics, Inc. (NASDAQ:SGEN) common shares that the Defendants made false and/or misleading statements and/or failed to disclose that vadastuximab talirine presents a significant risk of fatal hepatotoxicity, that as such, Seattle Genetics had overstated the viability of vadastuximab talirine as an acute myeloid leukemia (AML) treatment, and that as a result of the foregoing, Seattle Genetics' public statements were materially false and misleading at all relevant times.

On December 27, 2016, Seattle Genetics, Inc. (NASDAQ:SGEN) announced that it has received notice from the U.S. Food and Drug Administration ("FDA") that a clinical hold or partial clinical hold has been placed on several early stage trials of vadastuximab talirine (SGN-CD33A) in acute myeloid leukemia (AML). Shares of Seattle Genetics, Inc. (NASDAQ:SGEN) declined on December 27, 2016 to as low as $51.63 per share.

On January 17, 2016, NASDAQ:SGEN shares closed at $57.72 per share.

Those who purchased shares of Seattle Genetics, Inc. have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

Media Relations Contact

Michael Daniels
General Manager
Shareholders Foundation
858-779-1554
http://www.ShareholdersFoundation.com

View this press release online at: http://rwire.com/761254